What's happening
This bill requires pharmacies and pharmacy benefit managers to disclose prescription drug supply chain and country of origin information to patients.
Why it matters
Impacts all New Yorkers filling prescriptions. This bill applies statewide, meaning every pharmacy in New York, from major cities to rural areas, would be required to provide detailed information about where a drug and its ingredients come from, affecting millions of patients.
Increases transparency for patients, providers, and insurers. By mandating that pharmacies, and pharmacy benefit managers, share supply chain information—including the countries where drugs and their active ingredients are made—patients and healthcare professionals can make more informed choices and better understand potential risks tied to global manufacturing.
Establishes new state infrastructure and compliance standards. The bill directs the health commissioner to create a public electronic database for drug origin information and requires pharmacies to use standardized, consumer-friendly formats (labels, QR codes, or digital links), representing a significant expansion of current reporting and transparency requirements in New York law.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Patients and Consumers
Individuals receiving prescription drugs will benefit from greater transparency about where their medications are made and the origins of their ingredients, helping them make informed choices and feel confident in drug safety.
Pharmacies and Pharmacists
Pharmacies must provide new supply chain information to patients at the point of dispensing, requiring changes in labeling, documentation, and workflow.
Pharmacy Benefit Managers (PBMs) and Health Plans
PBMs will be responsible for collecting, maintaining, and sharing detailed supply chain data with pharmacies, health plans, and patients, affecting their data management and compliance operations.
Prescription Drug Manufacturers and Distributors
Companies that produce, pack, or distribute prescription drugs will face increased scrutiny and reporting requirements regarding the origin of drugs and active pharmaceutical ingredients, impacting their regulatory compliance and possibly their supply chain practices.
Headline styles
Show Drug Origins to Patients
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Require Drug Origin Disclosure
In Assembly Committee · Health · Sponsor Jake Ryan Blumencranz
Full text
3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
9985
IN SENATE
April 21, 2026
Introduced by Sen. RHOADS -- read twice and ordered printed, and when printed to be committed to the Committee on Health
AN ACT to amend the public health law and the education law, in relation to enhancing transparency in the prescription drug supply chain, including disclosure of country of origin and manufacturer information
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. This act shall be entitled the "foreign drug transparency act".
§ 2. Legislative intent. The legislature hereby finds and declares that:
1. The United States prescription drug supply chain is increasingly globalized, with a significant portion of finished drug products and active pharmaceutical ingredients (APIs) manufactured outside of the United States.
2. Patients, pharmacists, and health care providers often lack access to clear and accessible information regarding the origin and manufacturing of prescription drugs.
3. Transparency regarding the origin, manufacture, and distribution of prescription drugs is essential to ensuring patient confidence, informed decision-making, and supply chain accountability.
4. The legislature recognizes and supports ongoing bipartisan federal efforts, including the CLEAR LABELS Act, to require disclosure of drug manufacturing and supply chain information.
5. It is the intent of this act to complement federal law by ensuring that such information is readily accessible to consumers at the point of dispensing within New York State.
§ 3. Subdivision 1 of section 280-a of the public health law is amended by adding three new paragraphs (j), (k), and (l) to read as follows:
(j) "Active pharmaceutical ingredient" or "API" means any substance or component intended to furnish pharmacological activity in the diagnosis, cure, mitigation, treatment, or prevention of disease.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD15453-01-6
(k) "Original manufacturer" means the entity that performs the final substantial manufacturing step prior to the introduction of an API or finished drug product into interstate commerce.
(l) "Supply chain information" means:
(i) The country of origin of the finished drug product;
(ii) The country or countries of origin of any active pharmaceutical ingredients;
(iii) The name and place of business of the original manufacturer of the API;
(iv) The name and place of business of the manufacturer of the finished drug product; and
(v) The name and place of business of any packer or distributor, if applicable.
§ 4. Section 6810 of the education law is amended by adding a new subdivision 1-b to read as follows:
1-b.(a) In addition to the labeling requirements pursuant to subdivision one of this section, a pharmacy shall ensure that, at the time a prescription drug is dispensed to a patient, supply chain information, as defined in paragraph (l) of subdivision one of section two hundred eighty-a of the public health law, is made readily accessible to the patient.
(b) Such information shall be provided through one or more of the following methods:
(i) A clearly visible notation on the prescription label or accompanying documentation indicating the country of origin of the finished drug product;
(ii) A machine-readable code, including but not limited to a QR code, or a digital link that directs the patient to a publicly accessible source containing supply chain information; or
(iii) A printed or electronic document provided to the patient at the point of sale.
(c) Such disclosures shall be presented in a clear, conspicuous, and consumer-friendly manner, consistent with applicable federal law and regulations.
§ 5. Subdivision 2 of section 280-a of the public health law is amended by adding a new paragraph (f-1) to read as follows:
(f-1) (i) A pharmacy benefit manager shall maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.
(ii) Such information shall be transmitted in a standardized electronic format sufficient to enable compliance with the requirements of this title.
§ 6. The public health law is amended by adding a new section 278-b to read as follows:
§ 278-b. Electronic portal. The commissioner shall:
(a) Develop or designate a publicly accessible electronic portal or database through which patients may access supply chain information for prescription drugs dispensed within the state;
(b) Promulgate rules and regulations necessary to implement the provisions of this act, including standards for data formatting, accessibility, and consumer readability; and
(c) Ensure that implementation of this act is consistent with, and does not conflict with, federal law governing drug labeling and regulation.
§ 7. Construction. Nothing in this act shall be construed to require labeling or disclosures that are preempted by federal law, including the Federal Food, Drug, and Cosmetic Act. The provisions of this act shall be implemented to complement and align with federal requirements relating to drug labeling and supply chain transparency.
§ 8. This act shall take effect on the one hundred eightieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law and the education law, in relation to enhancing transparency in the prescription drug supply chain, includ- ing disclosure of country of origin and manufacturer information
Purpose
This bill will ensure that patients, pharmacists, and health care providers in New York State have meaningful access to information regarding the origin and manufacturing of prescription drugs, including active pharmaceutical ingredients, by requiring supply chain transparen- cy at the point of dispensing.
Summary of specific provisions
Section 1 establishes the short title as the "Foreign Drug Transparency Act." Section 2 sets forth legislative findings recognizing the globali- zation of the pharmaceutical supply chain, the lack of transparency currently available to patients and providers, and the importance of accessible information regarding drug origin and manufacturing.
Read the full memo (638 words)
Section 3 amends section 280-a of the public health law by adding defi- nitions for "active pharmaceutical ingredient," "original manufacturer," and "supply chain information," including country of origin and manufac- turer details.
Section 4 amends section 6810 of the education law to require pharmacies to make supply chain information readily accessible to patients at the time a prescription drug is dispensed. This may be accomplished through labeling, QR codes or digital links, or accompanying documentation, presented in a clear and consumer-friendly manner.
Section 5 amends section 280-a of the public health law to require phar- macy benefit managers to maintain and transmit supply chain information to pharmacies, health plans, and patients in a standardized electronic format.
Section 6 adds a new section 278-b to the public health law directing the Department of Health to develop or designate a publicly accessible electronic portal, promulgate regulations, and ensure compliance with federal law.
Section 7 provides that the act shall be implemented in a manner consistent with federal law and shall not require disclosures preempted by federal statute.
Section 8 sets forth the effective date.
Justification
The prescription drug supply chain has become increasingly globalized, with a substantial share of finished drug products and their active pharmaceutical ingredients manufactured outside the United States. Despite this reality, patients and providers are often left in the dark about where their medications originate. This lack of transparency undermines consumer confidence, limits informed decision-making, and obscures potential vulnerabilities within the pharmaceutical supply chain. Patients deserve access to clear, accu- rate, and actionable information about the medications they rely on-par- ticularly as concerns grow regarding reliance on foreign manufacturing.
This legislation addresses that gap by ensuring that supply chain infor- mation-such as country of origin and manufacturer details-is not only collected, but made readily accessible to patients at the point of care. By leveraging modern tools such as QR codes, digital links, and elec- tronic databases, the bill delivers transparency in a practical, scala- ble, and consumer-friendly manner.
Importantly, this bill is carefully structured to complement-not conflict with-federal law. It aligns with bipartisan federal efforts, including the CLEAR LABELS Act, which would require prescription drug labeling to include manufacturer and supply chain information, including the original manufacturer of active pharmaceutical ingredients and finished drug products.
While federal law governs drug labeling standards, this legislation operates within the State's authority to regulate pharmacy practice and consumer access to information. It ensures that once supply chain data exists, it is actually accessible and usable for patients in New York State.
New York has long been a leader in consumer protection and health care transparency. This legislation continues that tradition by bringing greater visibility and accountability to one of the most critical-and opaque-components of modern health care.
Legislative history
New bill.
Fiscal implications
Minimal.
Effective date
This act shall take effect on the one hundred eightieth day after it shall have become law. The Department of Health is authorized to promul- gate any necessary rules and regulations prior to such effective date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.